90 jili register sabong&slots
2025-01-11   

90 jili register sabong&slots Two of the I’m a Celebrity campmates took part in the Terrifying Teddy Bear’s Picnic, the first dreaded eating trial of the series. The Rev Richard Coles and Maura Higgins had to take part to win a junk food buffet for the whole camp. The two late arrivals, who have been separated from the main camp and have been living in luxury conditions with a proper bed, duvets, linen, food, a gas cooker and even a fridge stocked with smoothies and fresh fruit, unbeknown to the others, finally got a real taste of jungle life. In their final challenge to secure a junk food buffet for everyone, Richard and Maura still seemed to think the other campmates believed their sob story of no food and no beds but Coleen Rooney had sussed them out. At the picnic trial area Richard and Maura were told they had 12 picnic themed dishes and for every two they successfully ate or drank they would win another portion of food for the junk food buffet. Brought out by a ranger bear, Maura had ‘Porked Eye’ which was two pig’s eyeballs, whilst Richard tucked into a Crawl-Dorf Salad, where he had to eat five cockroaches and five crickets. But the late arrivals reigned victorious, successfully winning six more portions up for grabs at the junk food buffet and redeeming themselves from their Jungle Junkyard deception. The campmates learned they would have a feast of - burgers, hot dogs, chicken nuggets, pizza, onion rings and fries. But after tucking in to the mammoth meal two campmates were left with a sour taste in their mouths. Meanwhile, Ant swapped Dec for his wife as took a break from jungle duties to enjoy a stroll in the sunshine with Anne-Marie.LeBlanc and Joly offer little details about visit with Trump's team in Florida OTTAWA — Two senior members of the federal cabinet were in Florida Friday pushing Canada's new $1. Alessia Passafiume, The Canadian Press Dec 27, 2024 2:44 PM Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message Minister of Foreign Affairs Melanie Joly, centre, Prime Minister Justin Trudeau, right, and Dominic LeBlanc participate in a news conference in Ottawa, on Monday, Oct. 14, 2024. LeBlanc and Joly are in Florida to meet with officials from President-elect Donald Trump's incoming administration.THE CANADIAN PRESS/Justin Tang Listen to this article 00:01:24 OTTAWA — Two senior members of the federal cabinet were in Florida Friday pushing Canada's new $1.3 billion border plan with members of Donald Trump's transition team, a day after Prime Minister Justin Trudeau himself appeared to finally push back at the president-elect over his social media posts about turning Canada into the 51st state. Finance Minister Dominic LeBlanc and Foreign Affair Minister Melanie Joly shared few details of their meetings in Palm Beach, simply saying in a statement the U.S. officials they met with took notes and agreed to relay messages to Trump. "Minister LeBlanc and Minister Joly had a positive, productive meeting at Mar-a-Lago with Howard Lutnick and Doug Burgum, as a followup to the dinner between the prime minister and President Trump last month," wrote Jean-Sébastien Comeau, a spokesman for LeBlanc. Lutnick is Trump's nominee for commerce secretary, and Burgum is the former governor of North Dakota and current nominee for secretary of the interior. When announcing Lutnick as his commerce pick Trump said the chief executive of the financial firm Cantor Fitzgerald would be in charge of the Trump "tariff and trade agenda." "Both Ministers outlined the measures in Canada’s Border Plan and reiterated the shared commitment to strengthen border security as well as combat the harm caused by fentanyl to save Canadian and American lives." He added the ministers agreed to continue the discussions in the coming weeks. Joly is also expected to meet in Florida with senator Lindsay Graham Friday evening. This trip comes less than four weeks before Trump is sworn in again as president. He has threatened to impose a new 25 per cent import tariff on Canada and Mexico the same day over concerns about a trade imbalance, as well as illegal drugs and migration issues at the borders. The broad strokes of Canada's new border plan were made public Dec. 17, including a new aerial intelligence task force to provide round-the-clock surveillance of the border, and improved efforts using technology and canine teams to seek out drugs in shipments leaving Canada. Comeau said earlier Friday morning the ministers would also emphasize the negative impacts of Trump's threatened tariffs on both Canada and the U.S. Comeau said the ministers were to build on the discussions that took place last month when Trudeau and LeBlanc met Trump at Mar-a-Lago just days after Trump first made his tariff threat. It was at that dinner on Nov. 29 when Trump first raised the notion of Canada becoming the 51st state, a comment LeBlanc has repeatedly since insisted was just a joke. But Trump has continued the quip repeatedly in various social media posts, including in his Christmas Day message when he said Canadians would pay lower taxes and have better military protection if they became Americans. He has taken to calling Trudeau "governor" instead of prime minister. It isn't clear if LeBlanc raised the issue with Trump's team in Palm Beach Friday. Trudeau had not directly responded to any of the jabs, but on Thursday posted a link to a six-minute long video on YouTube from 2010 in which American journalist Tom Brokaw "explains Canada to Americans." "Some information about Canada for Americans" was all he wrote in the post. The video, which originally aired during the 2010 Vancouver Olympics, explains similarities between the two countries, including their founding based on immigration, their trading relationship and the actions of the Canadian Army in World War 2 and other modern conflicts. "In the long history of sovereign neighbours there has never been a relationship as close, productive and peaceful as the U.S. and Canada," Brokaw says in the video. Former Bank of Canada governor Mark Carney, who is at the centre of some of Trudeau's recent domestic political troubles, also called out Trump's antics on X Thursday, calling it "casual disrespect" and "carrying the 'joke' too far." "Time to call it out, stand up for Canada, and build a true North American partnership," said Carney, who Trudeau was courting to join his cabinet before Chrystia Freeland resigned as finance minister last week. Freeland's sudden departure, three days after Trudeau informed her he would be firing her as finance minister in favour of Carney, left Trudeau's leadership even more bruised than it already was. Despite the expectation Carney would assume the role, he did not and has not made any statements about it. LeBlanc was sworn in as finance minister instead the same day Freeland quit. More than two dozen Liberal MPs have publicly called on Trudeau to resign as leader, and Trudeau is said to be taking the holidays to think about his next steps. He is currently vacationing in British Columbia. He did not make a public statement about the meeting as of publication. This report by The Canadian Press was first published Dec. 27, 2024. Alessia Passafiume, The Canadian Press See a typo/mistake? Have a story/tip? This has been shared 0 times 0 Shares Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message More National News Vancouver's Bench Accounting abruptly shuts down, with 600 potential jobs lost Dec 27, 2024 2:17 PM Criminologist says Canada should better track foreign student departures Dec 27, 2024 2:13 PM B.C. man who flipped 14 homes in four years is fined $2M for tax evasion Dec 27, 2024 1:28 PM Featured Flyer

On Saturday, a stellar performance by India's fast bowler Jasprit Bumrah, who secured his 11th five-wicket haul, led to Australia's dismissal for a mere 104. This left India with a 46-run lead by lunch on the second day of the first test in Perth. Day one of the match saw 17 wickets fall, as India, too, was bowled out for 150. However, Bumrah's inspired bowling helped India gain momentum, leaving Australia struggling at 67-7 by stumps. Debutant Harshit Rana supported the attack, claiming crucial wickets early on day two. Mitchell Starc provided some resistance with a fighting 26-run inning but eventually fell victim to Rana's pace, bringing an end to Australia's innings. The partnership of Starc and Josh Hazlewood added 25 runs, but India maintained control thanks to their bowling prowess. (With inputs from agencies.)

None

CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $

SINGAPORE: It’s often said that the root cause of all conflicts boils down to ideological differences, competition for scarce resources, or just plain old insanity. If so, then an airplane cabin would be the perfect tinderbox. Case in point: An incident in September on a Cathay Pacific flight, where a couple took exception to the passenger in front of them reclining her seat. Their subsequent torrent of verbal abuse and physical harassment, caught on video and posted on social media platform Xiaohongshu, earned them a lifetime ban from the airline. We can have endless debates over the circumstances in which it’s appropriate to recline your seat, but really, it’s just one of many potential flashpoints in air travel these days. What about turf wars over armrests, or control of the window shade? If a middle seat is empty, how should the aisle and window passengers divide the spoils? Is it best practice for parents to hand out care packages, or does that set a dangerous precedent of apologising for having children? When passengers have to spend long hours together in tight spaces, it’s no wonder everyone quickly forms strong opinions about airplane etiquette. AIRLINE POLICIES RAISE THE TEMPERATURE To be sure, airlines deserve part of the blame. While First and Business Class cabins get more and more luxurious, the situation in Economy Class has steadily deteriorated. Airlines have been shrinking seats and reducing seat pitch (the distance between a seat and the one in front of it) to cram more passengers into the same aircraft. The unbundling trend, where perks which were once included for free are now chargeable, has progressively spread from budget carriers to full service ones. The end result, unsurprisingly, is all-out war. Because personal space is at a premium, any intrusion is more acutely felt. Because checking a bag is expensive, fights break out over limited overhead bin space. Because meals aren’t free, some passengers bring their own- and not everyone appreciates the smell of your favourite food as much as you do. Because selecting a seat costs money, not everyone does so, creating onboard drama when they demand that others switch seats to accommodate them. Sadly, there’s no sign of things abating. Every aircraft interiors expo sees the debut of slimmer and tighter seats, such as the infamous Aviointeriors Skyrider 3.0, a standing bicycle-like contraption straight from the works of Marquis de Sade. Closer to home, when Singapore Airlines finally replaces its ageing Boeing 777-300ERs with new Boeing 777-9s, it’s almost a given that the national carrier will go from 9-across seating in Economy Class to 10-across, reducing seat width accordingly. The cabin pressure, so to speak, is only going to increase. BUT PASSENGERS ARE NO ANGELS Airlines will counter that passengers are no angels themselves, and they’re not wrong. Even if personal space and creature comforts were provided in abundance, the core issue of selfishness would still remain. Technological advancements have put a smartphone into the hands of every traveller – but not everyone is considerate enough to watch movies with headphones. In-seat charging lets you land with a fully-charged battery- assuming your seatmate doesn’t hog the outlet. State-of the-art HEPA filters keep the cabin air clean- though that doesn’t help if the sick person next to you refuses to mask up. Now, it would be marvellous if open communication, graciousness and compassion prevailed. But you’ll forgive me for being more cynical, because my faith in humanity disappeared when a fellow passenger decided to put his phone alarm on perpetual snooze, waking the cabin every 10 minutes while he happily snored away. So a better approach would be, like French philosopher Sartre, to assume that hell is other people and prepare accordingly. WHAT CAN YOU DO? If personal space is a concern, some airlines offer the option of purchasing an empty middle seat (but that could open another can of worms, if a passenger feels entitled to use the space that you’ve paid for). Alternatively, buying a seat in the emergency exit row ensures that your legroom remains unimpeded, because the seats in front often don’t recline. Noise-cancelling headphones and earplugs go some way to drowning out snoring and loud conversations, and an eye-mask can be a lifesaver if your seatmate insists on keeping the reading light on throughout the night. And if push comes to shove, don’t take matters into your own hands. Seek help from the flight attendants, who are trained in de-escalation. Alternatively, you could, as I do, obsessively collect frequent flyer miles in the hope of escaping to the pointy end of the plane - though that’s no guarantee of civility, as I discovered on a recent Business Class flight where a fellow passenger hyena-laughed her way through every movie. When it’s all said and done, flying is a microcosm of human behaviour under pressure, a test of patience and restraint in a confined and stressful environment. While it would be lovely if empathy and good manners carried the day, the reality is that in close quarters, every small annoyance gets magnified. Beyond a certain point, all you can do is grin and bear it, and try to get to your destination with as little turbulence as possible. Aaron Wong is the founder of travel website The MileLion.PPP Chairman Bilawal Bhutto Zardari on Friday accused foreign powers, particularly the US, of interfering in Pakistan’s politics and added that they aimed to “strip us of our atomic power”. His comments came amid the US Department of State imposing sanctions related to Pakistan’s ballistic missile programme on December 18, targeting four entities that it alleged were contributing to the proliferation or delivery of such weapons. The day after the sanctions were imposed, senior White House official Jon Finer accused the country of developing long-range ballistic missile capabilities that could eventually allow it to strike targets outside of South Asia, including in the United States. Speaking during an event organised at the Bhutto family’s mausoleum in Larkana’s Ghari Khuda Bux to commemorate the 17th death anniversary of ex-premier Benazir Bhutto on Friday, Bilawal said: “I want to tell the whole world that as long as the PPP exists, we will not compromise on our atomic power or our missile programme.” “They are looking at our gifts with malicious intent and will take any excuse to strip you of your strength.” The PPP chairman emphasised the need for political stability to counter foreign interference, stressing that key decisions should be made through consensus to achieve that goal. “We need to unite in order to combat these conspiracies,” he said, adding that politics needed to be put to one side. In an apparent reference to the incoming US envoy for special missions Richard Grenell — who has been speaking up to free PTI founder Imran Khan from jail — Bilawal claimed that the statements were being used as “an excuse” to target Pakistan’s atomic capabilities. “Foreign nations are commenting on our internal politics as an excuse,” Bilawal said. Grenell has lately been making frequent public statements in support of Imran through his X account, garnering massive traction from PTI supporters both at home and abroad. In an interview with the US digital platform Newsmax on Wednesday, Grenell sharply criticised the Biden administration’s policies toward Pakistan, particularly its handling of the country’s missile programme and Imran’s imprisonment. Bilawal continued: “They do not care about human rights or prisoners. Imran Khan is an excuse, their only target is our atomic programme.” The PPP Charman went on to say that Imran should clarify that his party members are “against the missile technology given to us by Shaheed Mohtarma Benazir Bhutto”. “Why is he speaking for your rights?” Bilawal posed the question before the audience. He then accused the PTI of “raising their voices for Israel’s Zionist government and then for Pakistanis”, adding that the PTI should be condemned for “standing against Pakistan being an atomic power”. He alleged that Imran’s party was “creating a lobby” for governments who aim to weaken the country. The chairman vowed that the PPP and its workers would protect the country. Paying tribute to his late mother Benazir, he said that her 30-year-long political struggle cemented her place in history. “She became the first Muslim woman to hold the office of prime minister in the world,” he said. “She was not just a leader in Pakistan, but on the international stage. She raised your voices internationally and fought for your rights.” The Bhutto scion also lauded Benazir for bringing missile technology to Pakistan. “We all know that Zulfikar Ali Bhutto brought us atomic technology, and Benazir brought us missile technology. “Those who martyred her had the misconception that since she would be gone, the voices of Pakistanis would be silenced forever,” Bilawal added. “These people are ready to compromise on our values, our rights and our national security. They only care about the seat of power in Islamabad.” President Zardari then took the stage, praising the party’s supporters for their strength and thanking them for their prayers. “Through your strength, I am president once again,” Zardari said. “It is through your strength that 45 years later, we reversed Zulfikar Ali Bhutto’s verdict and proved that his martyrdom was judicial murder.” “With your prayers, we can overcome these difficult times,” he added. “There are difficulties and problems, but I will help you out of them. You will receive your rights, to water and gas, regardless of which province you are in.”

MALAGA, Spain (AP) — The last man to face — and beat — Rafael Nadal in professional tennis, 80th-ranked Botic van de Zandschulp , converted his 10th match point Friday to finally close out a 6-4, 6-7 (12), 6-3 victory over Daniel Altmaier and help the Netherlands reach its first Davis Cup final by sweeping Germany. Tallon Griekspoor, who is ranked 40th, sealed the 2-0 win for the Dutch in the best-of-three-match semifinal by hitting 25 aces and coming back to defeat Jan-Lennard Struff 6-7 (4), 7-5, 6-4. When it ended, appropriately, on an ace, Griekspoor shut his eyes, dropped to his knees and spread his arms wide. “We have been talking about this for two, three years,” Griekspoor said. “We believed in ourselves so much. We always felt like this was possible. To do it now feels unbelievable.” The other semifinal is Saturday, with No. 1-ranked Jannik Sinner and defending champion Italy taking on Australia . The championship will be decided Sunday. “We don’t have that top 5 player. We don’t that top 10 player. We don’t have that top 15 player,” Dutch captain Paul Harhuuis said. “But it’s a team effort. ... So proud of these guys.” In Friday's opener, van de Zandschulp was up a set and just a point away from leading 5-2 in the second when Altmaier began playing more aggressively and interacting more with the German fans, yelling and throwing uppercuts or raising his arms after key points. In the tiebreaker, Altmaier managed to save five match points before converting his own fourth set point to extend the contest. But van de Zandschulp — who upset four-time Grand Slam champion Carlos Alcaraz at the U.S. Open — quickly moved out front in the final set, even if he eventually needed five more match points in the last game before serving it out. “At some point, I didn’t know what to do any more on the match points,” van de Zandschulp said. “I had the toughest match of my life on Tuesday (against Nadal), so everything that comes next is maybe a little bit easier.” In the quarterfinals, van de Zandschulp outplayed Nadal for a 6-4, 6-4 result that marked the end of the 22-time Grand Slam champion’s career because the Netherlands went on to eliminate Spain 2-1. The 38-year-old Nadal announced last month that the Davis Cup would be his final event before retiring. Presumably because people purchased tickets ahead of time with plans to watch Nadal compete in the semifinals, there were hundreds of unoccupied blue or gray seats surrounding the indoor hard court at the Palacio de Deportes Jose Maria Martina Carpena in southern Spain on Friday. Now truly a neutral site, the place was not nearly as loud and rowdy as on Tuesday, although there were shouts of “Vamos, Rafa!” that drew laughter while van de Zandschulp played the 88th-ranked Altmaier. It took Griekspoor more than 75 minutes and nearly two full sets to figure out how to break No. 43 Struff and then did it twice in a row — to lead 6-5 in the second set, and then go up 1-0 in the third. That was plenty, because Griekspoor saved the only two break points he faced. The Netherlands hadn’t been to the semifinals since 2001. The Germans — whose best current player, two-time major finalist Alexander Zverev, is not on the team in Malaga — have won three Davis Cups, but not since 1993, when 1991 Wimbledon champion Michael Stich led them to the title. AP tennis: https://apnews.com/hub/tennisDANBURY, Conn., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Ethan Allen recently held its 2024 International Convention live at the Company's headquarters and livestreamed across the world. With the theme of Focused on the Future , the program honored the Company's 92-year history, reviewed current and future initiatives in manufacturing, logistics, technology, marketing and retail, and celebrated its annual Spirit Awards, honoring interior designers both for achievement in written sales and design excellence. Led by its Chairman, President and CEO Farooq Kathwari, the convention highlighted five key areas of focus for Ethan Allen: talent, service, marketing, technology, and social responsibility. "It was good to review all areas of our vertically integrated enterprise, to share new products and initiatives, and to celebrate the work and achievements of our team members. We take pride in sharing this special event with about 4,000 in attendance both watching and participating each year." Ethan Allen's annual convention is an important, decades-long tradition that gives its associates the opportunity to reconnect with colleagues from all over the world while they review the progress the Company has made over the past year. The Spirit Awards highlight Ethan Allen's interior design network, one of the world's largest, and emphasize the Company's unique combination of technology and personal service. The celebratory event concluded with Mr. Kathwari saying, "We are just getting started," as the Company is Focused on the Future . ABOUT ETHAN ALLEN Ethan Allen ETD , named America's #1 Premium Furniture Retailer by Newsweek for the second year in a row, is a leading interior design destination combining state-of-the-art technology with personal service. Our design centers, which represent a mix of independent licensees and Company-owned and operated locations, offer complimentary interior design service and sell a full range of home furnishings, including custom furniture and artisan-crafted accents for every room in the home. Vertically integrated from product design through logistics, we manufacture about 75% of our custom-crafted products in our North American manufacturing facilities and have been recognized for product quality and craftsmanship since 1932. Learn more at www.ethanallen.com and follow us on Facebook, Instagram, and LinkedIn. CONTACT: Catherine Plaisted Senior Vice President, Marketing catherine.plaisted@ethanallen.com Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/03602b41-d7d5-4e48-89b9-c4cf8d11a28f https://www.globenewswire.com/NewsRoom/AttachmentNg/f03d7cf2-d8e6-433e-afb3-45d6616ed037 https://www.globenewswire.com/NewsRoom/AttachmentNg/6dd9c843-54d2-4f8e-970f-e8a2d90d71ae © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

As tensions flare between Elon Musk and Trump’s MAGA allies, President-elect Donald Trump posted what appeared to be a personal message to Musk on Truth Social , claiming that fellow billionaire Bill Gates asked to come to Mar-a-Lago . In an early morning post on Friday, Trump suggested the Microsoft co-founder had asked to come to Mar-a-Lago. The 78-year-old Republican encouraged him to visit. “Where are you? When are you coming to the ‘Center of the Universe,’ Mar-a-Lago. Bill Gates asked to come, tonight. We miss you and x! New Year’s Eve is going to be AMAZING!!!” Trump wrote. He signed it “DJT.” It’s not immediately clear whether Gates would visit Trump at his Florida estate. The Independent has reached out to a representative for Gates for comment. Gates, whose net worth Forbes estimated to be more than $104 billion, reportedly first met with Trump in December 2016 after he clinched his first presidential election. He congratulated Trump after he won again in November. Trump has met with a handful of billionaires in recent weeks at Mar-a-Lago, including Amazon founderJeff Bezos and Meta CEO Mark Zuckerberg. “EVERYBODY WANTS TO BE MY FRIEND!!!” Trump boasted on Truth Social after dining with Bezos. The “X” mentioned in the post appears to be a reference to the Space X founder’s son, X Æ A-Xii , whom Musk calls X for short, CNN reported. The strange public note comes as Musk, Trump’s “best buddy”, has been clashing online with other close Trump allies over the H-1B visa program, which allows U.S. employers to hire highly skilled foreign workers. Musk and Vivek Ramaswamy, who together will head the newly created Department of Government Efficiency office, have defended the tech industry’s need to bring in foreign workers while Laura Loomer and others have criticized it. On Thursday, the feud escalated to a new level when Loomer accused Musk of removing her blue checkmark on X, the social media platform he owns, “because I dared to question his support for H1B visas, the replacement of American tech workers by Indian immigrants, and I questioned his relationship with China,” she wrote in a post . She continued: “Donald Trump promised to remove the H1B visa program and I support his policy. Now, as one of Trump’s biggest supporters, I’m having my free speech silenced by a tech billionaire for simply questioning the tech oligarchy.”Trump opposes TikTok ban, asks Supreme Court for time to resolve via negotiationsFrench President Emmanuel Macron accused Haiti's transitional council of being "total morons" for dismissing the country's prime minister, according to a video shot at the G20 summit in Brazil this week and shared on social media Thursday. In the footage, the French leader is speaking on the sidelines of the G20 in Rio with an individual accusing Macron and France of "being responsible for the situation in Haiti". Haiti's transitional council pushed out then-prime minister Garry Conille after just five months in office, a move Macron called "terrible" in the clip. "They're total morons," said Macron referring to the transitional body, adding, "they never should have dismissed him." Condemning the remarks, Haiti's Foreign Ministry said Thursday that French Ambassador Antoine Michon had been summoned following the "unacceptable comments." Haitian Minister of Foreign Affairs and Worship Jean-Victor Harvel Jean-Baptiste used the meeting to express "indignation" on behalf of the transitional council, which he said viewed the remarks as "an unfriendly and inappropriate gesture that must be rectified," according to a statement from the ministry. Haiti has suffered from decades of political instability. But in recent months, the Caribbean country has seen a surge in violence with gangs now controlling 80 percent of the capital, Port-au-Prince. The clip also shows the French president, who is on a multi-leg tour of Latin America with his most recent stop in Chile, blaming Haitians for "letting drug trafficking take over". "Quite frankly, it was the Haitians who killed Haiti," the French president said in the clip. Businessman Alix Didier Fils-Aime was sworn in as Haiti's new prime minister on November 12, promising to restore security in the crisis-wracked country. fff-lum/ekf/sjw/bfm/md

( MENAFN - EIN Presswire) IntriPlex Technologies has been recognized for its innovative contributions to domestic battery manufacturing, providing trusted and high-quality solutions. SANTA BARBARA, CA, UNITED STATES, December 27, 2024 /EINPresswire / -- energy Tech Review has recognized IntriPlex Technologies, Inc. as the Battery Metal Stamping technology Company of the Year 2025, a distinguished accolade highlighting IntriPlex's pioneering contributions to battery manufacturing. The award celebrates IntriPlex's unwavering dedication to precision engineering, innovation, and its trusted reputation among customers and industry leaders. “IntriPlex Technologies stood out due to its strong reputation and customer trust, demonstrated by the numerous nominations we received,” stated Energy Tech Review.“The company's commitment to advancing battery component technology and local manufacturing excellence positioned it as a clear winner.” With a mission to advance domestic battery manufacturing, IntriPlex Technologies specializes in designing and mass-producing critical battery components such as pressure vents and full lid assemblies. By employing state-of-the-art metal stamping and assembly techniques, the company provides battery manufacturers with a reliable, high-quality production alternative to overseas suppliers. President and CEO David Dexter emphasized IntriPlex's vision:“We aim to strengthen the domestic battery supply chain with innovative solutions and adequate capacity to help battery-makers improve efficiency while reducing their reliance on imports.” With the growing demand for electrification and renewable energy storage, IntriPlex is addressing a critical industry need for world-class, scalable production of precision components. The company operates two advanced manufacturing facilities, one in Santa Barbara, California, and the other in Ayutthaya, Thailand, ensuring responsiveness to both domestic and international markets. IntriPlex's commitment to research and innovation has led to groundbreaking advancements in production technologies. These efforts enable the company to meet exacting quality standards and deliver parts with micron-level precision. Looking to the future, IntriPlex is poised for continued expansion, with plans to establish additional manufacturing capabilities in the Eastern U.S. This move reflects the company's strategic focus on supporting domestic battery manufacturers as they scale operations to meet surging demand. About IntriPlex Technologies Based in Santa Barbara, California, IntriPlex Technologies has been a pioneer in metal stamping technologies since 1987, driving advancements in manufacturing for lithium-ion batteries, fiber optics, data storage, and medical applications. Committed to ongoing innovation, IntriPlex continuously develops and masters new metal stamping technologies to propel product evolution, enhance lives, and accelerate the transition to clean energy. Annemarie Niklasson IntriPlex Technologies +1 805-683-3414 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. MENAFN27122024003118003196ID1109035818 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

NoneBOCA RATON, Fla. (AP) — Deshawn Purdie threw a 47-yard touchdown pass to O'Mega Blake for the go-ahead score and Charlotte defeated Florida Atlantic 39-27 on Saturday in a game that matched two new interim coaches. Charlotte (4-7, 3-4 American Athletic Conference) fired Biff Poggi on Monday and Tim Brewster took over. FAU (2-9, 0-7) fired Tom Ferman, also on Monday, with Chad Lunsford taking charge. Javascript is required for you to be able to read premium content., /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended . "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. As of , the Company had in cash and cash equivalents. As of , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on . During the year ended , the Company received net proceeds of from the issuance of equity. The Company expects to raise additional capital to support operations. R&D expenses were for the full year ended , compared to for the full year ended . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. G&A expenses were for the full year ended , compared to for the full year ended . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. For the full year ended , stock-based compensation expense was as compared to for the prior year. The increase of is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was during the year ended , compared to for the year ended , as the plan was initiated in . For the years ended and 2023, stock-based compensation expense also includes and , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss was , or per share for the year ended , compared to a net loss of , or per share for the year ended , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of offset by a decrease of in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit . This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at , including in Citius Pharma's Annual Report on Form 10-K for the year ended , filed with the SEC on , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. 908-967-6677 x113 STiR-communications -- Financial Tables Follow –The No. 2 Ohio State Buckeyes made a statement on Saturday afternoon with their 38-15 blowout win over the No. 5 Indiana Hoosiers. There were a lot of questions coming into this game, like whether or not Indiana could compete with a top-ranked team in the nation, or if Ohio State's make-shift offensive line could keep things rolling in Columbus. A lot of those questions were answered, as the Buckeyes overcame a slow start to completely dominant the Hoosiers in ever facet of the game. When all was said and done, and the victory was in hand, Ohio State QB Will Howard broke out a celebration that has started to go viral on social media, trolling Indiana coach Curt Cignetti. © Adam Cairns/Columbus Dispatch / USA TODAY NETWORK via Imagn Images Howard mimicked the action of smoking a cigarette, throwing it on the ground, and stomping it out. This takes the cigarette theme that Indiana has used this year — for Coach Cignetti — and kicks it into the dirt. While some fans found it disrespectful to the opposing coach, for the most part the reaction was positive. Putting out a Cig...arette. https://t.co/o3LdcNhWQq Oh my god this rules https://t.co/tMeduzestu this is kinda hard ngl https://t.co/BidFBuwv0w This is beyond petty and I am here for it https://t.co/VyDjmtz0Xx I would die for Will Howard. https://t.co/qDTrAfYaaQ pic.twitter.com/xtifQQx82c Howard played well in the game, completing 22-of-26 passes for 201 yards, 2 touchdowns, and one interception. He also helped get the Buckeyes into a position now where they will likely face a rematch against the No. 1 Oregon Ducks in the Big Ten Championship Game in two weeks, assuming that they can beat the Michigan Wolverines in "The Big Game" next weekend. If Howard keeps playing the way he has been on the field, and keeps carrying that same swagger off of the field as well, this could be a special next month for the Buckeyes. Related: Alabama Transfer Caleb Downs Admits Ohio State Wasn't Prepared for Oregon After 'Easy' Schedule

Related hot word search:

Previous: 90 jili register online login
Next: 90/90-18 equivalent